Afatinib-related nonhematologic adverse events: is common evaluation enough for now?

J Clin Oncol. 2014 Mar 10;32(8):864-5. doi: 10.1200/JCO.2013.52.4538. Epub 2014 Feb 3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma of Lung
  • Afatinib
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • ErbB Receptors / genetics*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Quinazolines / therapeutic use*

Substances

  • Quinazolines
  • Afatinib
  • ErbB Receptors